Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy

Antiviral Therapy

Volumn 19, Issue 3, 2014, Pages 287-292

  Fernández Montero, José V ^a   Barreiro, Pablo ^a   Vispo, Eugenia ^a   Labarga, Pablo ^a   Sańchez Parra, Clara ^a   De Mendoza, Carmen ^a   Treviño, Ana ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; HEPATITIS B SURFACE ANTIGEN; LOPINAVIR; NEVIRAPINE; PEGYLATED INTERFERON PLUS RIBAVIRIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

ADULT; ALCOHOL ABUSE; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; ELASTOGRAPHY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; VIRAL CLEARANCE; BLOOD; COMPLICATION; DRUG EFFECTS; DRUG INTERACTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER CIRRHOSIS; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG INTERACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 84900394716     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2703     Document Type: Article

References (29)

1. Palella FJ, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
2. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24:1537-1548.
3. Wada N, Jacobson LP, Cohen M, et al. Cause-specific life expectancies after 35 years of age for HIV-infected and HIV-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116-125.
4. Puoti M, Moioli M, Travi G, et al. The burden of liver disease in HIV-infected patients. Semin Liver Dis 2012; 32:103-113.
5. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012; 32:138-146.
6. Hernandez MD, Sherman K. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011; 6:478-482.
7. Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010; 65:543-547.
8. Labarga P, Soriano V, Vispo E, et al. Hepatotoxicity of antiretroviral drugs is associated with reduced liver fibrosis after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670-676.
9. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
10. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
11. Jones M, Núñez M. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS 2011; 6:546-552.
12. Macías J, Mira JA, Lopez-Cortes L, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11:839-846.
13. Macías J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18:767-774.
14. Berenguer J, Bellón JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and Hepatitis C virus coinfection. Clin Infect Dis 2008; 46:137-143.
15. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:11-16.
16. Myers RP, Fong A, Shaheen A. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28:705-712.
17. Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49:1083-1089.
18. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
19. Kirk GD, Astemborski J, Mehta S, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-972.
20. Thompson MA, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 12 February 2013. Accessed 25 September 2013.) Available from http://aidsinfo.nih.gov/contentfiles/ lvguidelines/AdultandAdolescentGL.pdf
22. European AIDS Clinical Society. Guidelines version 6.1. (Updated November 2012. Accessed 25 September 2013.) Available from http://www.eacsociety.org/ Guidelines.aspx
23. Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198-1209.
24. Xu R, Zhang Z, Wang F. Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 2012; 9:296-301.
25. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
26. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13.
27. Mallet V, Gilgenkrantz H, Serpaggi J, et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399-403.
28. Thorpe J, Saeed S, Moodie E, et al . Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011; 25: 967-975.
29. Ganne-Carrié N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44:1511-1517.